Welcome to our dedicated page for FLUROTECH news (Ticker: FLURF), a resource for investors and traders seeking the latest updates and insights on FLUROTECH stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FLUROTECH's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FLUROTECH's position in the market.
FluroTech LTD. has appointed Dr. Joxel Garcia as Chief Medical Officer to enhance its global testing agenda for SARS-CoV-2. With a strong public health background, Dr. Garcia aims to expand FluroTest's diagnostic solutions. The firm confirms its high-volume testing system can detect multiple COVID-19 variants. Under his leadership, FluroTest is focused on obtaining regulatory approvals while engaging in clinical trials. The technology promises fast, reliable testing for high-risk environments, supporting safe economic activity amidst the ongoing pandemic.
FluroTech LTD. (OTCQB: FLURF) has signed a Memorandum of Understanding with SNC-Lavalin to aid in the deployment of its high-volume COVID-19 rapid antigen testing system. The partnership, initiated on May 6, 2021, will support regulatory submissions, grant applications, and operational phases of the testing platform. FluroTest's system aims to provide rapid, accurate testing for various high-risk environments, including airports and hospitals. Currently in clinical trials, FluroTest seeks FDA and Health Canada approvals for its testing technology.
FluroTech Ltd. (OTCQB: FLURF) has advanced its clinical trials for a rapid antigen testing system detecting SARS-CoV-2 across six U.S. sites, with 600 volunteers enrolled. This study aims to support Emergency Use Authorization submissions to the FDA and Health Canada. Toolbox Medical Innovations will assist in regulatory processes. CEO Bill Phelan emphasized the importance of the technology amid ongoing pandemic challenges. Despite achieving proof of concept, the technology is still pre-approval and cannot yet claim accurate detection of COVID-19.
FluroTech Ltd. (OTCQB: FLURF) announced that its FluroTest platform is capable of detecting various SARS-CoV-2 variants of concern, such as those from the UK, South Africa, and Brazil. The platform leverages advanced immunoassay technology to accurately identify the virus's nucleocapsid protein, which remains stable despite mutations. With the increasing transmissibility of these variants, the company emphasizes the need for widespread testing alongside vaccination to safely return to normalcy. FluroTest is currently in the pre-approval stage, and no express claims are made about the technology's capabilities.
FluroTech Ltd. has entered into a non-binding Memorandum of Understanding (MOU) with Total Testing Solutions (TTS) to launch a high-volume Covid-19 testing system in California. TTS, a major health testing provider, aims to conduct significant daily tests, enhancing public safety as venues reopen. FluroTest will provide the testing platform, while TTS manages operations. The initiative will leverage robotics, biochemistry, and cloud computing, seeking FDA Emergency Use Authorization. Though proof of concept exists, the technology is still awaiting regulatory approval.
FluroTech LTD. (OTCQB: FLURF) announced the appointment of former U.S. Public Health Service Four-Star Admiral Joxel Garcia, M.D. to its advisory board. Dr. Garcia, an expert in healthcare delivery and pandemic planning, will assist in preparing clinical trials for FluroTest's rapid antigen testing platform aimed at detecting SARS-CoV-2. FluroTest's technology is designed for high-throughput testing in various high-risk environments. The company is pursuing Emergency Use Authorization from the FDA and Health Canada to improve public health response amid rising COVID-19 variant cases.
FAQ
What is the market cap of FLUROTECH (FLURF)?
